Radiosynthesis and Preclinical Evaluation of 3′-Aza-2′-[18F]fluorofolic Acid: A Novel PET Radiotracer for Folate Receptor Targeting
- 17 January 2013
- journal article
- research article
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 24 (2) , 205-214
Abstract
The folate receptor (FR) has been identified as a valuable target for the imaging of cancer and activated macrophages, involved in inflammatory and autoimmune diseases via positron emission tomography (PET). Therefore, conjugates of folic acid have been synthesized by coupling of a radiolabeled prosthetic group to the glutamate part of folic acid (pendent approach). In this work, we present a novel class of folates, where the phenyl ring of folic acid was isosterically replaced by a pyridine moiety for direct labeling with [18F]fluoride (integrated approach). 3′-Azafolic acid and its 2′-halogenated derivatives (2′-chloro and 2′-fluoro) were evaluated in vitro to determine their binding affinity. 3′-Aza-2′-[18F]fluorofolic acid ([18F]6) was obtained, starting from N2-acetyl-3′-aza-2′-chlorofolic acid di-tert-butylester (2), in a maximum decay corrected radiochemical yield of about 9% in ≥98% radiochemical purity and high specific activities of 35–127 GBq/μmol. Binding affinity to the FR was high (IC50 = 0.8 ± 0.2 nM), and the radiotracer was stable in human plasma over 4 h at 37 °C. No degradation or defluorination was detected after incubation of the radiotracer for 1 h at 37 °C with human and murine liver microsomes and human S9-fraction. In vivo PET imaging and biodistribution studies with mice demonstrated a high and specific uptake in FR-positive KB tumor xenografts (12.59 ± 1.77% ID/g, 90 min p.i.). A high and specific accumulation of radioactivity was observed in the kidneys (57.33 ± 8.40% ID/g, 90 min p.i.) and salivary glands (14.09 ± 0.93% ID/g, 90 min p.i.), which are known to express the FR and nonspecific uptake found in the liver (10.31 ± 2.37% ID/g, 90 min p.i.). Preinjection of folic acid resulted in a >85% reduced uptake of [18F]6 in FR-positive tissues (xenografts, kidneys, and salivary glands). Furthermore, no radioactive metabolites were detected in the blood, urine, or tumor tissue, 30 min p.i. These characteristics indicate that this new 18F-labeled 3′-azafolate is an appropriate tool for imaging FR-positive (malignant) tissue.Keywords
This publication has 30 references indexed in Scilit:
- Engineering Folate–Drug Conjugates to Target Cancer: From Chemistry to ClinicBioconjugate Chemistry, 2012
- Farletuzumab, a Humanized Monoclonal Antibody against Folate Receptor α, in Epithelial Ovarian Cancer: a Phase I StudyClinical Cancer Research, 2010
- Clinical Pharmacokinetics and Exposure‐Toxicity Relationship of a Folate‐Vinca Alkaloid Conjugate EC145 in Cancer PatientsThe Journal of Clinical Pharmacology, 2009
- Folate-targeted therapeutic and imaging agents for cancerCurrent Opinion in Chemical Biology, 2009
- A functional folate receptor is induced during macrophage activation and can be used to target drugs to activated macrophagesBlood, 2009
- Synthesis and Discovery of High Affinity Folate Receptor-Specific Glycinamide Ribonucleotide Formyltransferase Inhibitors with Antitumor ActivityJournal of Medicinal Chemistry, 2008
- Discovery and Development of Folic-Acid-Based Receptor Targeting for Imaging and Therapy of Cancer and Inflammatory DiseasesAccounts of Chemical Research, 2007
- Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assayAnalytical Biochemistry, 2005
- Folate-targeted chemotherapyAdvanced Drug Delivery Reviews, 2004
- Folate receptor-mediated targeting of therapeutic and imaging agents to activated macrophages in rheumatoid arthritisAdvanced Drug Delivery Reviews, 2004